<DOC>
	<DOCNO>NCT02514629</DOCNO>
	<brief_summary>The purpose study examine effect metformin , testosterone , , males obesity-related hypogonadism . This study evaluate change insulin resistance , weight loss , body composition , testosterone level , quality life erectile dysfunction . Obese men receive diet physical activity counselling , randomise either testosterone , metformin , combination placebo</brief_summary>
	<brief_title>Testosterone , Metformin , Both , Hypogonadism Obese Males</brief_title>
	<detailed_description />
	<mesh_term>Obesity</mesh_term>
	<mesh_term>Hypogonadism</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Testosterone undecanoate</mesh_term>
	<mesh_term>Testosterone</mesh_term>
	<mesh_term>Testosterone enanthate</mesh_term>
	<mesh_term>Testosterone 17 beta-cypionate</mesh_term>
	<mesh_term>Methyltestosterone</mesh_term>
	<criteria>Men age 18 50 year . BMI &gt; = 30 kg/m2 . Total testosterone level &lt; 2.3 ng/ml ( &lt; 8 nmol/l ) testosterone level 2.33.49 ng/ml ( 812 nmol/l ) free testosterone level &lt; 70 pg/ml . LH level &lt; 7.7 mIU / ml . No evidence pituitary hormone disruption morning blood sample ( normal concentration TSH , FT4 , Prolactin , ACTH , cortisol IGF1 Being able provide inform consent randomization agree comply procedure include protocol . Intolerance/allergy metformin testosterone undecanoate . Previous diagnosis diabetes mellitus ( HbA1c &gt; 6.5 % fast glucose &gt; 126 mg/dl glucose &gt; 200 mg/dl oral glucose tolerance test ) Treatment oral hypoglycemic agent , insulin GLP1 analog . Poor kidney function : serum creatinine &gt; 2.0 mg / dl . Previous history prostate cancer breast cancer . Active cancer kind . History liver tumor acute chronic liver disease impair liver function : total bilirubin &gt; 2.0 mg / dl GOT level three time upper limit normal . Central hypogonadism organic cause Use past 12 month drug affect pituitarygonadal axis . Use oral testosterone , oral transdermal within 2 week prior study entry , testosterone ester last 6 week testosterone undecanoate injection 6 month prior study entry . Uncontrolled hypertension ( SBP &gt; 160 mmHg DBP &gt; 100 mmHg ) despite adequate antihypertensive therapy . HIV infection know active infection HBV HCV . Thrombotic embolic disease . Heart disease , kidney liver disease . Epilepsy migraine adequately control treatment . Hematocrit &gt; 50 % screening . PSA &gt; 4 ng / ml . Severe benign prostatic hypertrophy IPSS scale score 19 . Evidence drug alcohol abuse ( &gt; 50 g alcohol / day ) Hematological diseases produce increase risk bleed intramuscular injection . Serious underlie disease might affect patient 's ability participate study ( eg ongoing infection , gastric ulcer , active autoimmune disease ) . Reduced life expectancy ( &lt; 12 month ) presence comorbidities advance terminal . Participation another clinical trial within 30 day study entry . Previous diagnosis hemochromatosis Treatment phosphodiesterase5 inhibitor : sildenafil , tadalafil vardenafil</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Hypogonadism</keyword>
	<keyword>Obesity</keyword>
	<keyword>Erectile Dysfunction</keyword>
	<keyword>Testosterone</keyword>
	<keyword>Metformin</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Insulin Resistance</keyword>
</DOC>